http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-069244-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e9522e625f762330fe22dfe11685f76 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| filingDate | 2008-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-069244-A1 |
| titleOfInvention | METHODS FOR MANAGING N- (5- TER- BUTIL- ISOXIXASOL-3-IL) -N'- (4 (7- (2- MORFOLIN-4-IL-ETOXI) IMIDAZO (2,1-B) (1,3 ) BENZOTIAZOL -2-IL) PHENYL) UREA TO TREAT A PROLIFERANT DISEASE AND PHARMACEUTICAL COMPOSITION |
| abstract | Claim 1: A method of treating a proliferative disease in a mammal, comprising administering to a mammal suffering from or suspected of having the proliferative disease, a therapeutically effective amount of the compound of the formula (1) or a pharmaceutically acceptable salt or solvate acceptable thereof, wherein the therapeutically effective amount is at least 12 mg per day. Claim 10: The method of any one of claims 1 to 9, wherein the proliferative disease is cancer. Claim 11: The method of claim 10, wherein the cancer is a leukemia. Claim 22: The method of any one of claims 1 to 21, further comprising administering to the subject a therapeutically effective amount of a second therapeutic agent. Claim 23: The method of claim 22, wherein the second therapeutic agent is an anticancer agent. Claim 24: The method of claim 23, wherein the anticancer agent is selected from the group consisting of adriamycin, busulfan, cytarabine, cyclophosphamide, dexamethasone, fludarabine, fluorouracil, hydroxyurea, interferons, oblimersen, platinum derivatives, taxol, topotecan and Vincristine Claim 25: The method of claim 23, wherein the anticancer agent is a FLT3 kinase inhibitor selected from the group consisting of PKC 412, MLN 578, CEP-701, CT 53518, CT-53608, CT-52923, D -64406, D-65476, AGL-2033, AG1295, AG1296, KN-1022, PKC-412, SU5416, SU5614, SU11248, L-00021649 and CHIR-258. Claim 26: The method of any one of claims 1 to 25, further comprising a diagnostic step to determine the presence of a constitutively active mutant FLT3. Claim 28: The method of claim 10, wherein the cancer is bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, cancer of lung, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, cancer of thyroid, uterine cancer or hematological malignancies. |
| priorityDate | 2007-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.